GH2616 Tablets

Developed for: cancer
Investigated by: Henan Cancer Hospital · Hubei Cancer Hospital · Suzhou Genhouse Bio Co., Ltd. · The First Affiliated Hospital of Zhengzhou University · Zhejiang Cancer Hospital

today NCT06329206 · Ph 1

20252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06329206	Mar 2024 → Apr 2026 overdue	cancer	Suzhou Genhouse Bio Co., Ltd.	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	GH2616 Tablets	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06329206 ↗
Route	Oral	“GH2616 tablets will be given orally” NCT06329206 ↗